Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03992027 · ClinicalTrials.gov registry record · NA

Preventing Depression and Anxiety: A Cystic Fibrosis-Specific Cognitive Behavioral Therapy Intervention

A NA study of Depression and Anxiety, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
60
Enrollment target
4
Study locations

NCT03992027: Completed NA study of Depression and Anxiety, sponsored by Massachusetts General Hospital.

NCT03992027 is a NA study of Depression and Anxiety that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03992027, a NA study of Depression and Anxiety, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
4
Study locations

Study Summary

Individuals with Cystic Fibrosis (CF) are at high risk for depression and anxiety, with negative consequences for quality of life, ability to carry out daily CF treatments, and health. CF Foundation and European CF Society guidelines recommend routine screening, treatment, and preventative efforts for depression and anxiety. Cognitive-behavioral therapy (CBT) interventions focused on teaching coping skills have a large evidence-base for prevention and treatment of depression and anxiety, but there are barriers to accessing these interventions for individuals with CF. Drs. Friedman and Georgiopoulos at Massachusetts General Hospital (MGH) have developed a CF-specific CBT-based preventive intervention for depression and anxiety with input from adults with CF and CF healthcare team members, called CF-CBT: A cognitive-behavioral skills-based program to promote emotional well-being for adults with CF, along with a training and supervision program for CF team interventionists. CF-CBT consists of 8 45-minute modules that can be flexibly delivered in the outpatient CF clinic, on the inpatient unit, or by telephone, by multidisciplinary members of the CF care team, minimizing additional cost and burden of care to patients. The goal of this study is to test CF-CBT in 60 adults screening in the mild range on measures of depression and anxiety at 4 CF centers, in a prospective randomized clinical trial comparing the intervention to usual treatment. Participants will be randomized to receive the CF-CBT intervention immediately, or to a 3-month waitlist control followed by intervention. The study will measure depression, anxiety, quality of life, stress, and coping self-efficacy before and after the CF-CBT intervention, and also 3 and 6 months post-intervention.

Primary Outcome

The PHQ-9 consists of nine questions measuring frequency of depressive symptoms, rated on a Likert scale from 0 "not at all" to 3 "nearly every day," with total score ranging 0-27. Clinical severity scores have been established with scores of 5, 10, 15, and 20 representing cut-off scores for mild, moderate, moderately severe, and severe depression, respectively.

Conditions Studied

Interventions

  • BEHAVIORAL Waitlist Control
  • BEHAVIORAL CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis

Study Locations (4)

California

  • Stanford University - Palo Alto

Kansas

  • University of Kansas Medical Center - Kansas City

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • University at Buffalo - Buffalo

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-07-22
Est. Completion 2022-10-31
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT03992027 record still lists

NCT03992027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Waitlist Control is the first listed.

NCT03992027 reports a single indexed study location in California, Kansas, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03992027 about?

NCT03992027 is a clinical study titled "Preventing Depression and Anxiety: A Cystic Fibrosis-Specific Cognitive Behavioral Therapy Intervention". Individuals with Cystic Fibrosis (CF) are at high risk for depression and anxiety, with negative consequences for quality of life, ability to carry out daily CF treatments, and health. CF Foundation and European CF Society guidelines recommend routine screening, treatment, and preventative efforts f...

What is the current status of trial NCT03992027?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2019-07-22. Estimated completion is 2022-10-31.

What conditions does trial NCT03992027 study?

This clinical trial studies the following conditions: Depression, Anxiety.

What interventions are being tested in trial NCT03992027?

The interventions under investigation include: Waitlist Control (BEHAVIORAL), CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis (BEHAVIORAL).

Who is sponsoring clinical trial NCT03992027?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03992027 being conducted?

This trial has 4 study locations across California, Kansas, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03992027's enrollment target sits among peer trials

60 428th of 679 higher than 234 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03992027, the US trial registry maintained by the National Library of Medicine. NCT03992027 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.